- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
CYTX Market Currents
more »
-
March 16 Cytori Therapeutics (CYTX) +9.5% premarket after announcing it received 510(k) clearance from the FDA for its Puregraft 850 System for body contouring using a patient's own fat.
Comment![Healthcare, On the Move]
CYTX in Focus
more »
CYTX Related Articles
more »
CYTX News
more »
-
at MarketWatch.com (Jul 13, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at MarketWatch.com (Jun 8, 2011)
-
at MarketWatch.com (Mar 2, 2011)
CYTX Press Releases and Filings
more »
-
Marketwire (Wed, 8:00AM)
-
Marketwire (May 9, 2012)
-
Marketwire (Apr 27, 2012)
-
Marketwire (Mar 19, 2012)
-
Marketwire (Mar 16, 2012)
CYTX Latest Transcript
more »
CYTX Cramer
more »
Currently, there are no Cramer articles on CYTX.
CYTX Instablog posts
more »
CYTX vs. ETF Alternatives
Company Description
Cytori Therapeutics, Inc., develops, manufactures, and sells medical products to enable the practice of regenerative medicine. Regenerative medicine describes the emerging field that aims to repair or restore lost or damaged tissue and cell function. Our commercial activities are currently... More
